Sadaf Yousuf, MD
Family Medicine · Mandan, NDNPI 1457607632
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 62 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations.
Across 62 payments — averaging $17.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$213
- AstraZeneca$168
- Amgen$128
- AbbVie$82
- E.r. Squibb & Sons, L.L.C.$61
- Boehringer Ingelheim$59
- plus $382 from 13 others
What the payments were for
- Food & beverage$1,092100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 13 | $213 |
| AstraZeneca | 3 | $168 |
| Amgen | 9 | $128 |
| AbbVie(2 entities) | 5 | $82 |
| E.r. Squibb & Sons, L.L.C. | 3 | $61 |
| Boehringer Ingelheim | 4 | $59 |
| Merck | 3 | $57 |
| Daiichi Sankyo Inc. | 2 | $51 |
| Lilly USA, LLC | 4 | $50 |
| Novartis | 3 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Pfizer | 2 | $29 |
| Johnson & Johnson | 2 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 2 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
| Novo Nordisk | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,092 in reported general payments places this provider in the 80th percentile of 337 family medicine providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 82 | $70,296 |
| JardianceEmpagliflozin | 65 | $65,658 |
| OzempicSemaglutide | 53 | $63,556 |
| MounjaroTirzepatide | 19 | $20,294 |
| XareltoRivaroxaban | 16 | $18,885 |
| TrulicityDulaglutide | 14 | $13,087 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 12 | $11,063 |
| Atrovent HfaIpratropium Bromide | 18 | $8,213 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 12 | $7,156 |
| Metoprolol Succinate | 185 | $4,070 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $3,995 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $3,838 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 13 | $3,788 |
| Atorvastatin Calcium | 272 | $3,506 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $3,284 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr | $59 | $83,87789 claims |
| PfizerEliquis, Abrysvo | $29 | $74,08395 claims |
| Novo NordiskOzempic | $14 | $63,55653 claims |
| Lilly USA, LLCMounjaro, Trulicity | $50 | $33,38133 claims |
| Johnson & JohnsonXarelto | $27 | $18,88516 claims |
| AstraZenecaSymbicort | $168 | $3,28415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 337 family medicine providers in North Dakota.
Other family medicine in Mandan
- Thomas ThorsonMandan$241K
- Anthony JohnsonMandan$7K
- Dale KleinMandan$3K
- Gretchen Belzer CurlMandan$3K
- Meghan HendricksonMandan$3K
- Andrew DockterMandan$983
- Richard VetterWest Fargo$294K
- Gregory GreekGrand Forks$216K
- Katherine NeubauerWest Fargo$160K
- Spencer BerryFargo$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.